Daito Pharmaceutical Co Ltd
TSE:4577

Watchlist Manager
Daito Pharmaceutical Co Ltd Logo
Daito Pharmaceutical Co Ltd
TSE:4577
Watchlist
Price: 2 025 JPY 0.35% Market Closed
Market Cap: 31.1B JPY
Have any thoughts about
Daito Pharmaceutical Co Ltd?
Write Note

Daito Pharmaceutical Co Ltd
Cash from Financing Activities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Daito Pharmaceutical Co Ltd
Cash from Financing Activities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash from Financing Activities CAGR 3Y CAGR 5Y CAGR 10Y
Daito Pharmaceutical Co Ltd
TSE:4577
Cash from Financing Activities
-ÂĄ183m
CAGR 3-Years
N/A
CAGR 5-Years
42%
CAGR 10-Years
22%
Takeda Pharmaceutical Co Ltd
TSE:4502
Cash from Financing Activities
ÂĄ50.4B
CAGR 3-Years
N/A
CAGR 5-Years
-53%
CAGR 10-Years
N/A
Daiichi Sankyo Co Ltd
TSE:4568
Cash from Financing Activities
-ÂĄ232.5B
CAGR 3-Years
-8%
CAGR 5-Years
-22%
CAGR 10-Years
-9%
Otsuka Holdings Co Ltd
TSE:4578
Cash from Financing Activities
ÂĄ44.1B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Chugai Pharmaceutical Co Ltd
TSE:4519
Cash from Financing Activities
-ÂĄ139.3B
CAGR 3-Years
-9%
CAGR 5-Years
-16%
CAGR 10-Years
-19%
Astellas Pharma Inc
TSE:4503
Cash from Financing Activities
-ÂĄ122.4B
CAGR 3-Years
16%
CAGR 5-Years
3%
CAGR 10-Years
0%
No Stocks Found

Daito Pharmaceutical Co Ltd
Glance View

Market Cap
31B JPY
Industry
Pharmaceuticals

Daito Pharmaceutical Co., Ltd. engages in the development, production, and sale of pharmaceutical products. The company is headquartered in Toyama-Shi, Toyama-Ken and currently employs 846 full-time employees. The company went IPO on 2010-03-24. The pharmaceutical ingredients business is engaged in the manufacture, purchase, sale and entrusted manufacture business of pharmaceutical ingredients used as raw materials for pharmaceutical manufacture and formulation. The formulation business is engaged in the manufacture, purchase, sale and entrusted manufacture business of prescription pharmaceuticals and pharmaceuticals for general-use medicines.

Intrinsic Value
2 429.67 JPY
Undervaluation 17%
Intrinsic Value
Price

See Also

What is Daito Pharmaceutical Co Ltd's Cash from Financing Activities?
Cash from Financing Activities
-183m JPY

Based on the financial report for Aug 31, 2024, Daito Pharmaceutical Co Ltd's Cash from Financing Activities amounts to -183m JPY.

What is Daito Pharmaceutical Co Ltd's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 10Y
22%

Back to Top